Short Interest in XOMA Royalty Corporation (NASDAQ:XOMA) Grows By 27.4%

XOMA Royalty Corporation (NASDAQ:XOMA) was the recipient of a significant increase in short interest in the month of January. As of January 30th, there was short interest totaling 1,051,282 shares, an increase of 27.4% from the January 15th total of 824,924 shares. Based on an average daily trading volume, of 783,079 shares, the short-interest ratio is currently 1.3 days. Approximately 9.1% of the shares of the stock are short sold. Approximately 9.1% of the shares of the stock are short sold. Based on an average daily trading volume, of 783,079 shares, the short-interest ratio is currently 1.3 days.

Insider Activity

In other news, CEO Owen Hughes acquired 100,000 shares of XOMA Royalty stock in a transaction that occurred on Thursday, December 4th. The stock was bought at an average price of $25.05 per share, with a total value of $2,505,000.00. Following the completion of the purchase, the chief executive officer owned 102,000 shares in the company, valued at approximately $2,555,100. The trade was a 5,000.00% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available through this link. Insiders own 7.20% of the company’s stock.

Institutional Inflows and Outflows

Several large investors have recently made changes to their positions in the business. Woodline Partners LP lifted its holdings in shares of XOMA Royalty by 16.5% in the 3rd quarter. Woodline Partners LP now owns 209,945 shares of the biotechnology company’s stock worth $8,091,000 after acquiring an additional 29,715 shares during the last quarter. Vanguard Group Inc. raised its position in XOMA Royalty by 4.6% in the 3rd quarter. Vanguard Group Inc. now owns 668,111 shares of the biotechnology company’s stock worth $25,749,000 after purchasing an additional 29,298 shares during the period. Stonepine Capital Management LLC lifted its stake in XOMA Royalty by 17.2% in the second quarter. Stonepine Capital Management LLC now owns 152,143 shares of the biotechnology company’s stock worth $3,834,000 after purchasing an additional 22,330 shares during the last quarter. Occudo Quantitative Strategies LP purchased a new stake in XOMA Royalty during the second quarter valued at about $527,000. Finally, Panagora Asset Management Inc. bought a new position in shares of XOMA Royalty during the second quarter valued at about $463,000. 95.92% of the stock is owned by hedge funds and other institutional investors.

XOMA Royalty Price Performance

XOMA opened at $24.01 on Monday. The company has a current ratio of 3.91, a quick ratio of 3.91 and a debt-to-equity ratio of 1.07. The stock has a market capitalization of $297.24 million, a P/E ratio of 32.45 and a beta of 0.86. The stock has a 50-day moving average price of $26.44 and a 200-day moving average price of $31.15. XOMA Royalty has a 12-month low of $18.35 and a 12-month high of $39.92.

Analysts Set New Price Targets

XOMA has been the topic of several research analyst reports. UBS Group set a $76.00 price target on shares of XOMA Royalty in a report on Tuesday, December 9th. TD Cowen upgraded XOMA Royalty to a “hold” rating in a research note on Friday. Weiss Ratings reaffirmed a “hold (c-)” rating on shares of XOMA Royalty in a report on Monday, December 29th. HC Wainwright dropped their price target on XOMA Royalty from $104.00 to $97.00 and set a “buy” rating for the company in a research report on Thursday, December 11th. Finally, Leerink Partners decreased their price objective on shares of XOMA Royalty from $58.00 to $45.00 and set an “outperform” rating on the stock in a research report on Thursday, December 11th. Three research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company. Based on data from MarketBeat, XOMA Royalty currently has a consensus rating of “Moderate Buy” and an average target price of $60.60.

About XOMA Royalty

XOMA Royalty (NASDAQ: XOMA) is a specialty healthcare royalty company that acquires and manages royalty interests in small-molecule and biologic drugs. The company’s business model centers on purchasing royalty streams on marketed or near-market pharmaceutical products, providing capital to developers in exchange for a share of future net sales. By focusing on late-stage assets with established clinical and commercial profiles, XOMA Royalty aims to generate predictable, long-term cash flows for its shareholders.

The company’s investment portfolio spans a range of therapeutic areas, including oncology, immunology and rare diseases.